Researchers Identified Daraxonrasib Resistance Patterns
New study details how advanced pancreatic cancers bypass a recently approved treatment.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should medical research prioritize developing new drugs or combining existing cancer therapies?
Researchers found that pancreatic cancer cells may overproduce the KRAS protein to develop resistance to the drug daraxonrasib. This development, which typically occurs after seven months of treatment, was recently highlighted following the clinical case of former senator Ben Sasse.
Why it matters
Understanding how tumors evade targeted therapy is a critical step in overcoming treatment resistance in advanced pancreatic cancer. These findings offer potential pathways for improving long-term outcomes by refining how clinicians approach drug combinations.
A study of 66 patients with advanced pancreatic cancer analyzed biopsies and blood samples to determine how tumors respond to daraxonrasib over time. The findings indicate that tumors eventually evade the drug by overproducing the KRAS protein.
The players
Ben Sasse
Former senator from Nebraska who publicly shared his experience with pancreatic cancer drug resistance.
AACR
The American Association for Cancer Research, a professional organization dedicated to accelerating progress against cancer through research and education.
The details
Daraxonrasib works by targeting cancer cells, initially cutting their numbers in half within two weeks of treatment and doubling median survival. However, researchers discovered that after seven months, surviving cancer cells adapt by overproducing the KRAS protein, making them behave more like cells that respond to standard chemotherapy. This shift suggests that the tumor environment actively changes its internal signaling to bypass the drug's primary mechanism of action.
Timeline
August 2026: Daraxonrasib received official drug approval.
September 2026: Former senator Ben Sasse announced his cancer developed drug resistance.
September 25, 2026: Study results were presented at an AACR conference in San Diego.
Health Landscape
This study highlights the ongoing challenge of drug resistance within the broader context of cancer treatment development. It adds critical data to the field of over 90 KRAS inhibitors currently being tested in clinical trials.
Patients currently taking targeted therapies like daraxonrasib should discuss potential changes in their tumor markers with their oncology team. It is worth asking your doctor about how your care plan accounts for the possibility of treatment resistance and if new combination therapies might be appropriate.
The takeaway
Pancreatic cancer cells often develop resistance to targeted therapies like daraxonrasib by shifting their biological signaling pathways. Patients undergoing long-term targeted treatment should track any changes in symptom patterns or imaging results and discuss these updates with their physician.
Further reading
For more on evolving research in oncology, visit our Cancer section.
Source note: This article includes information reported by The New York Times.
Live Poll
Should medical research prioritize developing new drugs or combining existing cancer therapies?
